SEP 12, 2018 12:00 PM PDT

ONETest PathoGenome: A Target Hybridization-Based Next-Generation Sequencing Assay to Tackle Undiagnosed Infections

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • President & Chief Scientific Officer, Fusion Genomics
    Biography
      Dr Qadir's training is in genetics and molecular biology. Dr Qadir has over 17 years of research experience. The last ten were at the British Columbia Cancer Agency where he worked with world-renowned experts in genomics and drug development. Dr Qadir is the co-inventor of the CHILDSeq-Sarcoma assay and CHILDDecode (part of FUSIONCloud™). Dr Qadir oversees all the scientific aspects of research and development efforts at FUSION GENOMICS and also serves as the interface for all collaborators.

    Abstract

    Every year, approximately 800,000 critically ill patients are hospitals in the USA with undiagnosed infections. The only option is to treat these patients with broad-spectrum antimicrobial therapy and hope for the best outcome. The inability to obtain specific actionable information in a clinically relevant time-frame, combined with ineffective treatment, contributes to increased disease burden, mortality, hospitalizations, and drug resistance. The consequence is direct hospitalization costs of more than $27 billion, with another $26 billion lost due to antimicrobial resistance. What is urgently needed is precise and comprehensive targeted pathogen identification, including the capacity to detect drug-resistant mutations, for routine diagnosis to support effective treatment and control measures.
    Fusion Genomics Corp.’s mission is to address this need and enable precision medicine for infectious diseases by developing a pan-pathogen test - the ONETest™ PathoGenome - that identifies all human pathogens (~1,400) and provides the genomic information necessary to guide treatment, including drug resistance and human genetic susceptibility markers in a timely fashion. The assay uses next-generation DNA sequencing (NGS) along with Fusion’s novel DNA hybridization technology, QuantumProbes, to enrich bacterial/viral/fungal genomes prior to sequencing. The assay will be functionally equivalent, yet clinically superior, to whole metagenome sequencing, but at 1/10th the cost, 1/3rd the time, and several times the sensitivity.

    Learning Objectives: 

    1. learn how NGS will impact undiagnosed infections  
    2. learn about the advantages of using targeted sequencing versus whole metagenome sequencing


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources
    Attendees
    • See more